
|Videos|August 24, 2022
Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM
Author(s)Sunandana Chandra, MD, MS
An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CURE
1
U.S. Soccer Legend Kasey Keller Reveals Lymphoma Journey
2
Why Is Lung Health Key to Survivorship After Cancer Treatment?
3
New Combination Treatment Approach Studied in Pancreatic Cancer
4
The Power of Personalized Care in Breast Cancer Treatment
5

